321 filings
Page 5 of 17
8-K
j7d1dyr
23 Feb 23
180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application
8:32am
8-K
y0y 56k2xdsv
22 Feb 23
Regulation FD Disclosure
4:32pm
8-K
bsu43p
16 Feb 23
Regulation FD Disclosure
2:50pm
8-K
o5hxmyne04qrmev3utyi
20 Jan 23
Departure of Directors or Certain Officers
8:03am
8-K
rib o9fgng5
18 Jan 23
Entry into a Material Definitive Agreement
4:28pm
8-K
e8s67km9h81 ylqro
17 Jan 23
180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
8:00am
8-K
s9yp6
12 Jan 23
Entry into a Material Definitive Agreement
5:00pm
8-K
a8ms6
5 Jan 23
Other Events
9:30am
8-K
c89yk234
4 Jan 23
180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
8:30am
8-K
4dkgrx2jkn3kb3
29 Dec 22
Entry into a Material Definitive Agreement
4:30pm
8-K
mhr4z84r31b1x2m3
29 Dec 22
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
8:30am
8-K
z4s e88o64
22 Dec 22
180 Life Sciences Corp. Announces $6 Million Registered Direct Offering
5:15pm
424B5
c3nfgy pcp2
22 Dec 22
Prospectus supplement for primary offering
5:12pm
8-K
30in3kybrkahsmbge1q
16 Dec 22
180 Life Sciences Corp. Announces 1-FOR 20 Reverse Stock Split As Part of Nasdaq Compliance Plan
9:00am
8-K
39009hklrbl 23qjl4y
30 Nov 22
Regulation FD Disclosure
5:00pm
8-K
8hohe7
15 Nov 22
Adalimumab Found To Be a Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
4:15pm